Table 1.
RT Mutations More Frequent at Virologic Failure than at Pre-therapy (N=53 pairs)a
| Domain | Mutation | % Pre-therapy(N)b | % Failure(N)b | p-valuec |
|---|---|---|---|---|
| Polymerase | K65R | 0(0) | 7.6(4) | 0.13 |
| V90I | 0(0) | 3.8(2) | 0.50 | |
| K101E | 0(0) | 5.7(3) | 0.25 | |
| K103N | 1.9(1) | 23(12) | 0.001 | |
| V106I/M | 1.9(1) | 9.4(5) | 0.13 | |
| V179D | 3.8(2) | 7.6(4) | 0.50 | |
| M184I/V | 1.9(1) | 15(8) | 0.016 | |
| Y188H | 0(0) | 3.8(2) | 0.50 | |
| G190S | 0(0) | 5.7(3) | 0.25 | |
| Connection | R358K | 7.6(4) | 11(6) | 0.63 |
| A376S | 1.9(1) | 5.7(3) | 0.50 | |
| M/T377L | 13(7) | 17(9) | 0.50 | |
| RNase H | V467I | 17(9) | 23(12) | 0.25 |
| K530R | 4.1(2) | 8.2(4) | 0.50 | |
a
Mutations ≥3% more frequent at virologic failure compared to pre-therapy.
b
Total N=53 except K530R (N=49, 4 subtype C sequences were excluded from analysis because they differed from subtype B consensus).
c
Exact McNemar’s test (two-sided).